Your browser is no longer supported. Please, upgrade your browser.
Settings
STOK [NASD]
Stoke Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.09 Insider Own0.40% Shs Outstand36.76M Perf Week-19.44%
Market Cap847.91M Forward P/E- EPS next Y-2.59 Insider Trans-30.93% Shs Float19.91M Perf Month-4.84%
Income-75.90M PEG- EPS next Q-0.73 Inst Own53.00% Short Float12.38% Perf Quarter-13.85%
Sales- P/S- EPS this Y-46.10% Inst Trans-4.38% Short Ratio16.91 Perf Half Y-40.90%
Book/sh6.46 P/B3.53 EPS next Y-8.00% ROA-27.70% Target Price60.44 Perf Year-53.69%
Cash/sh6.36 P/C3.59 EPS next 5Y- ROE-28.90% 52W Range21.42 - 71.58 Perf YTD-63.14%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.11% Beta-
Dividend %- Quick Ratio20.60 Sales past 5Y- Gross Margin- 52W Low6.58% ATR1.86
Employees79 Current Ratio20.60 Sales Q/Q- Oper. Margin- RSI (14)35.90 Volatility7.55% 6.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-49.50% Profit Margin- Rel Volume0.92 Prev Close24.90
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout- Avg Volume145.74K Price22.83
Recom1.90 SMA20-16.08% SMA50-10.42% SMA200-31.57% Volume134,226 Change-8.31%
Nov-22-21Upgrade JP Morgan Neutral → Overweight $41
May-18-21Initiated UBS Neutral $35
May-10-21Upgrade Wedbush Neutral → Outperform
Apr-26-21Resumed Credit Suisse Outperform $58
Feb-10-21Downgrade Wedbush Outperform → Neutral
Dec-15-20Resumed H.C. Wainwright Buy $70
Dec-11-20Reiterated Needham Buy $48 → $56
Oct-23-20Initiated Cantor Fitzgerald Overweight $49
Sep-29-20Resumed JP Morgan Neutral $34
Sep-29-20Initiated Needham Buy $42
Dec-18-19Initiated Wedbush Outperform $31
Nov-12-19Initiated BTIG Research Buy $46
Oct-25-19Initiated H.C. Wainwright Buy $30
Jul-15-19Initiated JP Morgan Overweight $34
Jul-15-19Initiated Credit Suisse Outperform $35
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $44
Nov-30-21 09:16AM  
Nov-22-21 07:20AM  
Nov-19-21 11:54AM  
Nov-08-21 07:00AM  
Nov-04-21 11:28AM  
Nov-03-21 07:30AM  
Sep-22-21 04:30PM  
Sep-21-21 12:46PM  
06:59AM  
Sep-13-21 12:51PM  
Aug-10-21 07:00AM  
Aug-03-21 08:00AM  
May-18-21 07:30AM  
May-10-21 07:30AM  
May-04-21 08:00AM  
Mar-30-21 07:30AM  
Mar-24-21 07:30AM  
Mar-15-21 09:39AM  
Mar-09-21 09:31AM  
07:30AM  
Mar-04-21 07:30AM  
Feb-26-21 06:15AM  
06:00AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Jan-22-21 08:00AM  
Jan-19-21 08:00AM  
Jan-06-21 08:00AM  
Jan-05-21 10:00AM  
Jan-04-21 04:05PM  
Dec-25-20 03:06AM  
Dec-17-20 08:00AM  
Dec-10-20 10:33PM  
Dec-04-20 04:05PM  
09:57AM  
Dec-02-20 04:05PM  
Nov-30-20 08:00AM  
Nov-25-20 07:30AM  
Nov-24-20 04:01PM  
Nov-19-20 07:00PM  
08:17AM  
Nov-18-20 04:02PM  
Nov-12-20 07:38AM  
Nov-11-20 09:00AM  
Nov-10-20 06:37AM  
Nov-09-20 07:30AM  
07:30AM  
06:15AM  
06:00AM  
Nov-05-20 10:51AM  
Nov-04-20 08:00AM  
Nov-02-20 08:00AM  
07:30AM  
Oct-14-20 05:05PM  
Oct-08-20 07:52AM  
Oct-07-20 07:00AM  
Sep-29-20 12:23PM  
09:50AM  
Sep-21-20 12:41PM  
Sep-17-20 06:00AM  
Sep-15-20 03:41PM  
11:48AM  
Sep-10-20 08:00AM  
Sep-09-20 07:30AM  
Sep-03-20 08:00AM  
Sep-02-20 04:05PM  
Aug-31-20 08:00AM  
Aug-26-20 02:00PM  
Aug-17-20 07:30AM  
Aug-11-20 12:25PM  
08:00AM  
Aug-10-20 07:30AM  
Aug-07-20 06:00AM  
Aug-04-20 12:19PM  
08:00AM  
07:30AM  
Jul-31-20 08:00AM  
Jul-09-20 05:40AM  
Jul-08-20 04:15PM  
Jun-24-20 12:27PM  
Jun-04-20 08:00AM  
May-15-20 07:00AM  
May-12-20 08:00AM  
Mar-23-20 08:00AM  
Feb-24-20 08:00AM  
Jan-08-20 07:30AM  
Jan-07-20 08:30AM  
Dec-23-19 08:30AM  
Dec-19-19 04:51PM  
Dec-08-19 10:00AM  
Dec-07-19 12:00PM  
Dec-06-19 02:23PM  
Nov-26-19 08:30AM  
08:30AM  
Nov-25-19 11:00AM  
11:00AM  
Nov-22-19 06:43AM  
Nov-12-19 08:00AM  
Nov-05-19 08:30AM  
Oct-28-19 02:12PM  
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nash Huw M.COO & CBONov 03Option Exercise2.191,9004,1611,900Nov 03 06:05 PM
Nash Huw M.COO & CBONov 03Sale25.001,90047,5000Nov 03 06:05 PM
Nash Huw M.COO & CBONov 01Option Exercise2.193,8008,3223,800Nov 03 06:05 PM
Nash Huw M.COO & CBONov 01Sale23.543,80089,4560Nov 03 06:05 PM
Nash Huw M.COO & CBOOct 01Option Exercise2.195,70012,4835,700Oct 04 05:51 PM
Nash Huw M.COO & CBOOct 01Sale24.835,700141,5060Oct 04 05:51 PM
Nash Huw M.COO & CBOSep 01Option Exercise2.195,70012,4835,700Sep 02 06:30 PM
Nash Huw M.COO & CBOSep 01Sale26.005,700148,2230Sep 02 06:30 PM
Nash Huw M.COO & CBOAug 02Option Exercise2.195,70012,4835,700Aug 04 07:41 PM
Nash Huw M.COO & CBOAug 02Sale28.875,700164,5540Aug 04 07:41 PM
Ticho BarryChief Medical OfficerJul 13Sale32.7543,1661,413,654130,895Jul 15 07:29 PM
Nash Huw M.COO & CBOJun 01Option Exercise2.195751,259575Jun 03 05:48 PM
Nash Huw M.COO & CBOJun 01Sale39.4357522,6690Jun 03 05:48 PM
Liau GeneEVP Research & Preclinical DevMar 02Option Exercise0.605,1953,11726,546Mar 04 05:00 PM
Liau GeneEVP Research & Preclinical DevMar 02Sale63.055,195327,54621,351Mar 04 05:00 PM
LEVIN ARTHUR ADirectorMar 01Option Exercise0.5312,5006,57612,500Mar 03 05:10 PM
LEVIN ARTHUR ADirectorMar 01Sale60.7912,500759,8410Mar 03 05:10 PM
Tulipano Stephen JCFOFeb 23Option Exercise4.485,00022,4005,602Feb 24 05:15 PM
Tulipano Stephen JCFOFeb 23Sale58.605,000292,992602Feb 24 05:15 PM
Tulipano Stephen JCFOFeb 22Option Exercise4.4825,000112,00025,602Feb 24 05:15 PM
Tulipano Stephen JCFOFeb 22Sale58.9225,0001,472,904602Feb 24 05:15 PM
TZIANABOS ARTHURDirectorFeb 19Option Exercise2.1910,00021,90010,000Feb 23 05:28 PM
TZIANABOS ARTHURDirectorFeb 19Sale60.6710,000606,6520Feb 23 05:28 PM
Nash Huw M.COO & CBOJan 06Sale57.14321,8280Jan 06 05:26 PM
Nash Huw M.COO & CBOJan 04Option Exercise2.195,70012,4835,732Jan 06 05:26 PM
Nash Huw M.COO & CBOJan 04Sale58.975,700336,15732Jan 06 05:26 PM
Kaye Edward M. MDCEODec 30Option Exercise0.6010,0006,00010,000Jan 04 06:33 PM
Liau GeneEVP Research & Preclinical DevDec 28Option Exercise0.608,0004,80021,500Mar 04 05:00 PM
Liau GeneEVP Research & Preclinical DevDec 28Sale58.731498,75121,351Mar 04 05:00 PM
Ticho BarryChief Medical OfficerDec 21Option Exercise2.191,3652,989174,767Dec 21 04:53 PM
Ticho BarryChief Medical OfficerDec 21Sale57.621,36578,654173,402Dec 21 04:53 PM
Nash Huw M.COO & CBODec 18Option Exercise0.608,0154,8098,015Dec 18 09:08 PM
Kaye Edward M. MDCEODec 18Sale60.005,194311,6400Dec 18 09:07 PM
Nash Huw M.COO & CBODec 18Sale60.008,015480,9000Dec 18 09:08 PM
Nash Huw M.COO & CBODec 17Option Exercise0.6041,98525,19141,985Dec 18 09:08 PM
Kaye Edward M. MDCEODec 17Sale60.0019,8061,188,3605,194Dec 18 09:07 PM
Nash Huw M.COO & CBODec 17Sale60.0041,9852,519,1000Dec 18 09:08 PM